Unexpected Complication of a Multinodular Goitre
Paulien MM van Hauten1, Gysele S Bleumink2, Marcel MC Hovens3, Ton AJM Rijnders4, Ruth Ekhart2
1Department of Internal Medicine, Rijnstate Hospital Arnhem, Arnhem, The Netherlands
2Department of Endocrinology, Rijnstate Hospital Arnhem, Arnhem, The Netherlands
3 Department of Vascular Medicine, Rijnstate Hospital Arnhem, Arnhem, The Netherlands
4Department of Nuclear Medicine, Rijnstate Hospital Arnhem, Arnhem, The Netherlands
Doi: 10.12890/2015_000363 - European Journal of Case Reports in Internal Medicine - © EFIM 2016
Received: 18/12/2015
Accepted: 18/12/2015
Published: 22/01/2016

How to cite this article: van Hauten PMM, Bleumink GS, Hovens MCC, Rijnders TAJM, Ekhart R. Unexpected complication of a multinodular goitre EJCRIM 2016;3:doi:10.12890/2016_000363

Conflicts of Interests: The authors declare there are no competing interests.

This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT

Multinodular goitre is the most common thyroid gland disorder. It can cause hyperthyroidism and mechanical complaints such as tracheal compression or dysphagia. We report a unique case of a patient with a toxic multinodular goitre presenting with a deep venous thrombosis of the left arm due to direct local compression of blood flow.

LEARNING POINTS

KEYWORDS

Hyperthyroidism, multinodular goitre, venous thromboembolism.

INTRODUCTION

Multinodular goitre (MNG) is a thyroid gland disorder common in general practice and with a prevalence of 0.7 per 1,000 patients. It tends to grow slowly but steadily. Symptoms are related to the growth and hormonal activity of the tissue. Compression of the trachea, the oesophagus and neural structures causes dyspnoea, orthopnoea, asphyxia, dysphagia, dysphonia and Horner’s syndrome. Symptoms of hyperthyroidism include anxiety, weight loss, palpitations, heat sensitivity and tremors. The prevalence of malignancy in MNG is approximately 3–5%, which is lower than that in single nodules. Here we describe an uncommon and relatively unknown but potentially life-threatening complication of MNG.

CASE REPORT

AA 89-year-old woman without a relevant medical history apart from a recently diagnosed toxic MNG was admitted to the hospital with nausea and diarrhoea. Treatment with strumazol had already reduced the thyroxine level from 94 pmol/l to 48 pmol/l in 1 week. The working diagnosis was gastrointestinal complaints due to hyperthyroidism caused by MNG. At admittance, physical examination revealed a painless swelling of the left arm with pitting oedema. Duplex ultrasound showed thrombosis in the left jugular vein and subclavian vein with distal collateralization. Computed tomography (CT) showed a large retrosternal mass originating from the left thyroid lobe with extension into the mediastinum upon the aortic arch, causing displacement and stenosis of the trachea and located adjacent to the brachiocephalic vein causing compression of blood flow (Fig. 1).
The patient was started on anticoagulation therapy. Thorough anamnesis, physical examination, chest x-ray and abdominal ultrasound revealed no signs of associated malignancy.

Figure 1 (click to enlarge)

Figure 1. CT scan, coronal plane, showing a large goitre with displacement of the trachea

DISCUSSION

Toxic MNG is a common benign cause of hyperthyroidism. This case shows that toxic MNG can be associated with venous thrombosis of the upper extremity due to mechanical alterations in blood flow and chemical hypercoagulability provoked by hyperthyroidism.

Venous thrombosis

The incidence of deep venous thrombosis of the upper extremity (UEDVT) and the internal jugular vein has been increasing since the common use of central venous catheters was introduced. The underlying pathophysiological processes of Virchow’s triad result in a broad spectrum of predisposing factors (Table 1)[1].
Patients with a thrombosis of the upper extremity present with a tired, heavy feeling in their arm accompanied by pain. Physical examination shows swelling of the arm with a restricted range of motion and dilated cutaneous veins. The differential diagnosis includes lymphoedema or an inflammation of the skin. A diagnostic algorithm combining the Constans clinical score, D-dimer testing and, when indicated, ultrasonography is a safe and effective method to exclude thrombosis in patients with suspected UEDVT[2]. Early severe complications of UEDVT include pulmonary embolism (2.7–36%) and intracranial propagation of the thrombus (17.5%). In the long term, patients may experience arm swelling, pain and discomfort due to valvular damage and residual mural thrombus leading to post-thrombotic syndrome. Anticoagulation therapy is the first-choice treatment in the early phase and should be continued for at least 3 months, depending on predisposing factors.

Table 1 (click to enlarge)

Table 1: Risk factors for deep venous thrombosis of the arm.

This case shows that the slow and steady growth of a substernal goitre can cause UEDVT. This condition has been described only rarely in the literature[1,3,4]. UEDVT can be the presenting symptom of a previously silent substernal goitre[3]. The slow growth rate of a substernal goitre usually permits the development of a collateral circulation.

Hyperthyroidism

As described above, venous thromboembolism (VTE) has a multifactorial aetiology due to numerous genetic and acquired risk factors. Hyperthyroidism is also pathophysiologically and clinically associated with VTE. Patients with hyperthyroidism show elevated levels of vWF and enhanced platelet function, elevated levels of coagulation factors VIII and IX, fibrinogen and plasminogen activator inhibitor-1 (PAI-1) and decreased levels of plasminogen activator (t-PA). This results in a hypercoagulable and hypofibrinolytic state which returns to normal after successful treatment of the hyperthyroidism. A retrospective multicentre cohort study of 587 patients with a first episode of hyperthyroidism showed a higher incidence of VTE compared to the general population (8.7 versus 0.7–1.8 per 1,000 person-years), with the majority of thrombotic events occurring before diagnosis and before anti-thyroid pharmacotherapy[5].

CONCLUSION

In conclusion, this case report describes a thrombosis in the left jugular vein and subclavian vein caused by a toxic MNG compressing the innominate vein. Circulatory stasis and chemical hypercoagulability both contributed to the pathophysiological process. UEDVT is associated with benign substernal goitre and hyperthyroidism and can be the first presenting symptom.

References
  1. Lønnebakken MT, Pedersen OM, Andersen KS, Verhaug JE. Incidental detection of internal jugular vein thrombosis secondary to undiagnosed benign substernal goiter. Case Rep Med 2010;645193.
  2. Kleinjan A, Di Nisio M, Beyer-Westendorf J, Camporese G, Cosmi B, Ghirarduzzi A, et al. Safety and feasibility of a diagnostic algorithm combining clinical probability, D-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis. Ann Intern Med 2014;160:451–457.
  3. Hauer Santos G, Ghalili K. Axillosubclavian vein thrombosis produced by retrosternal thyroid. Chest 1990;98:1281–1283.
  4. Khan AM, Khan S. Retrosternal thyroid mass resulting in axillosubclavian vein thrombosis. BMJ Case Rep 2014 Feb 5;2014. pii: bcr2013202450. doi: 10.1136/bcr-2013-202450 (accessed 4 Jan 2016).
  5. Kootte RS, Stuijver DJF, Dekkers OM, van Zaane B, Fliers E, Cannegieter SC, et al. The incidence of venous thromboembolism in patients with overt hyperthyroidism. Thromb Haemost 2012;107:417–422.